Revised total sales for 3 products to JPY 27.7 billion considering first half results - initial plan was JPY 29.9 billion.
Vigorous marketing to boost sales
Results of comparative study for patients with depression in Japan became available
• Significant differences observed compared to other antidepressants
• Launched new marketing activities utilizing this evidence in May
Fast-acting, unique feature - expand sales further
Approved for long-term prescription in June
• One year since launch of sales
• Sales expanding rapidly
Establish firm presence in the market and boost sales
• Will be approved for long-term prescription in December
• Peak period for allergic rhinitis (hay fever), December through March, is coming.
Revised total sales for 3 products to JPY 27.7 billion considering first half results - initial plan was JPY 29.9 billion.
ReflexVigorous marketing to boost sales
Results of comparative study for patients with depression in Japan became available
• Significant differences observed compared to other antidepressants
• Launched new marketing activities utilizing this evidence in May
SycrestFast-acting, unique feature - expand sales further
Approved for long-term prescription in June
• One year since launch of sales
• Sales expanding rapidly
BilanoaEstablish firm presence in the market and boost sales
• Will be approved for long-term prescription in December
• Peak period for allergic rhinitis (hay fever), December through March, is coming.